Progress of Auto-HSCT for Treatment of DLBCL--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1841-1846, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-774375
ABSTRACT
Diffuse large B cell lymphoma(DLBCL)is the most common non-Hodgkin's lymphoma in adults,accounting for 30%-40% of non-Hodgkin's lymphoma in adults. The treatments of this lymphoma mainly include chemotherapy,radiotherapy and autologous hematopoietic stem cell transplantation. A large amount of studies show that autologous hematopoietic stem cell transplantation considered as the main treatmant approach can be used for primary high-risk young and relapsed or refractory DLBCL patients. Many scholars have evaluated the effectiveness of autologous hematopoietic stem cell transplantation for primarily high-risk young and relapsed or refractory DLBCL patients,and tried to improve the effectiveness of transplantation that showed some advantagcs for DLBCL patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Transplantation, Autologous
/
Antineoplastic Combined Chemotherapy Protocols
/
Lymphoma, Large B-Cell, Diffuse
/
Treatment Outcome
/
Hematopoietic Stem Cell Transplantation
/
Transplantation Conditioning
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS